8-K: NeoGenomics Q3 2025 Revenue Up 12%, Reaffirms Guidance

NeoGenomics, Inc. reported a 12% year-over-year increase in third-quarter 2025 consolidated revenue to $188 million, driven by strong clinical and NGS revenue growth, while reaffirming its full-year financial guidance.

Summary

• Consolidated revenue for the third quarter of 2025 increased 12% year-over-year to a record $188 million.
• Clinical revenue grew 18% year-over-year, or 15% excluding the Pathline acquisition.
• Next-Generation Sequencing (NGS) revenue increased 24% year-over-year and now accounts for nearly one-third of clinical revenue.
• Net loss for the quarter increased 53% to $27 million, compared to a net loss of $18 million in the third quarter of 2024.
• Adjusted EBITDA was positive $12.2 million, a decline of 9% from $13.4 million in the prior year.
• The company re-affirmed its full-year 2025 guidance for consolidated revenue ($720 million $726 million), net loss ($(116) million $(108) million), and adjusted EBITDA ($41 million $44 million).
• Average revenue per clinical test increased by 3% to $476, with 4% growth excluding recently acquired Pathline tests.
• Consolidated gross profit was $80 million, an increase of 7% compared to the third quarter of 2024, with a GAAP gross profit margin of 43% and an Adjusted Gross Profit Margin of 45%.
• Operating expenses increased 12% to $107 million, primarily due to $7.1 million of impairment charges related to the planned sale of Trapelo and $4.7 million in higher compensation and benefit costs.
• Cash and cash equivalents and marketable securities totaled $164 million at quarter end.

Sentiment

Score: 7

Explanation: While net loss increased and Adjusted EBITDA declined, the company achieved record revenue, strong clinical and NGS growth, and reaffirmed its full-year guidance, suggesting underlying business strength and confidence in future performance despite some operational challenges and non-clinical weakness. The strong performance in high-growth segments like NGS is a positive indicator.

Positives

• Consolidated revenue reached a record $188 million, marking a 12% increase year-over-year.
• Clinical revenue demonstrated strong growth of 18% year-over-year, or 15% excluding the Pathline acquisition.
• Next-Generation Sequencing (NGS) revenue grew 24% year-over-year, significantly outpacing the low-to-mid-teens NGS market growth rate.
• NGS now constitutes nearly one-third of clinical revenue, indicating a successful shift towards higher-value testing.
• Average revenue per clinical test increased by 3% to $476, reflecting a favorable test mix and effective reimbursement strategies.
• The company re-affirmed its full-year 2025 guidance for revenue, net loss, and adjusted EBITDA, signaling confidence in its financial outlook.

Negatives

• Net loss increased significantly by 53% year-over-year, reaching $27 million compared to $18 million in the third quarter of 2024.
• Adjusted EBITDA declined 9% year-over-year to $12.2 million from $13.4 million in the prior year.
• Operating expenses increased by $11 million, or 12%, primarily driven by $7.1 million in impairment charges related to the planned sale of Trapelo and $4.7 million in higher compensation and benefit costs.
• Adjusted Net Income decreased to $3.6 million from $6.9 million in the third quarter of 2024.
• Non-clinical revenue experienced continued weakness, although this was anticipated and factored into the full-year guidance.
• Cash and cash equivalents and marketable securities decreased from $367 million at December 31, 2024, to $164 million at September 30, 2025.

Risks

• The company's ability to identify and implement appropriate financial and operational initiatives to improve performance.
• The ability to assemble and maintain an effective executive team.
• Challenges in continuing to gain new customers and offer new types of tests.
• Risks associated with integrating acquisitions.
• The impact of seasonality on business operations.
• The ability to execute on long-range strategic priorities and implement business plans effectively.
• Changing reimbursement levels from government payers and private insurers.
• General risks identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequently filed Quarterly Reports on Form 10-Q.

Future Outlook

The company re-affirmed its full-year 2025 guidance for revenue, net loss, and adjusted EBITDA, anticipating continued growth in clinical volumes, including NGS testing, to drive performance in the fourth quarter and position for increased momentum entering 2026. Management expressed optimism for the company's future, emphasizing its role as a partner of choice for clinicians in community settings.

Management Comments

• "During the third quarter, we again delivered strong clinical test volumes and revenue while advancing our long-term growth initiatives in therapy selection and MRD – two of the largest and fastest growing areas of cancer testing with significant unmet needs."
• "Total revenue of $188 million increased 12% year-over-year, driven by the continued expansion of our clinical business, which grew by 18%."
• "Notably, NGS grew 24% year-over-year, well ahead of the low-to-mid-teens NGS market growth rate, and now accounts for nearly one-third of our clinical revenue."
• "I am pleased with how the core business is tracking, notwithstanding continued weakness in non-clinical revenue, which we anticipated and incorporated into the full-year guidance that we are re-affirming today."
• "We believe continued growth in our clinical volumes, including NGS testing, will drive performance in the fourth quarter while positioning us to enter 2026 with increased momentum."
• "Our relentless focus on the customer experience, which is enabled by our broad, oncology-centric test menu, world class commercial organization, and balanced geographic footprint, continues to differentiate us in the community setting, where approximately 80% of cancer care is delivered."
• "At NeoGenomics, our goal has long been to bring the latest cancer testing innovation to community hospitals and oncologists, where its needed most, and I believe we have become the partner of choice for these clinicians who strive every day to achieve the best possible outcomes for their patients."
• "I am as optimistic as ever for what the future holds for our company."

Industry Context

NeoGenomics operates in the rapidly expanding oncology diagnostics market, specifically targeting precision medicine, therapy selection, and minimal residual disease (MRD) testing. The company's 24% year-over-year growth in Next-Generation Sequencing (NGS) revenue significantly outpaces the broader NGS market growth rate of low-to-mid-teens, indicating strong competitive positioning and market share gains in a high-growth segment. Its focus on community settings, where 80% of cancer care is delivered, aligns with a strategy to broaden access to advanced testing and solidify its market presence.

Comparison to Industry Standards

• NeoGenomics' Next-Generation Sequencing (NGS) revenue growth of 24% year-over-year significantly exceeds the stated low-to-mid-teens NGS market growth rate, indicating strong performance relative to the overall industry trend.

Legal Proceedings

• IP litigation costs of $3.6 million were incurred for the three months ended September 30, 2025, and $11.1 million for the nine months ended September 30, 2025, primarily consisting of legal fees.

Stakeholder Impact

• Shareholders: Experienced mixed results with strong revenue growth in core segments but increased net loss and decreased Adjusted EBITDA. The reaffirmation of full-year guidance provides some stability and predictability.
• Customers (Oncologists, Pathologists, Hospital Systems, Academic Centers, Pharmaceutical Firms): Benefit from the company's continued focus on customer experience, broad oncology-centric test menu, and efforts to bring the latest cancer testing innovation to community settings.
• Employees: Higher compensation and benefit costs indicate ongoing investment in the workforce, though the mention of CEO transition costs and acquisition-related expenses suggests some organizational restructuring.

Next Steps

• Drive performance in the fourth quarter through continued growth in clinical volumes, including NGS testing.
• Position the company to enter 2026 with increased momentum.
• Hold a conference call to discuss Q3 2025 results on October 28, 2025, at 8:30 a.m. Eastern Time.

Key Dates

Recommendation

The company demonstrated strong top-line growth in its core clinical and NGS segments, outperforming market rates in NGS. However, this growth was offset by a significant increase in net loss and a decline in Adjusted EBITDA, partly due to impairment charges and higher operating costs. The reaffirmation of full-year guidance provides some stability, but the mixed financial performance suggests a 'hold' recommendation as investors await clearer signs of profitability improvement and successful integration of initiatives like the Trapelo sale.

Keywords

Oncology Diagnostics, Precision Medicine, Cancer Testing, NGS, Clinical Revenue, Financial Results, Q3 2025, NeoGenomics, Pathline, Trapelo, MRD, Biotechnology